BNP Paribas Asset Management
ALXN

BNP Paribas Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

BNP Paribas Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-180,816
Closed -$33.2M – 939
2021
Q2 		$33.2M Sell
180,816
-2,072
-1% -$356K 0.12% 213
2021
Q1 		$28M Buy
182,888
+164,409
+890% +$25.4M 0.12% 212
2020
Q4 		$2.89M Sell
18,479
-325
-2% -$41.8K 0.01% 578
2020
Q3 		$2.15M Sell
18,804
-5,147
-21% -$555K 0.01% 585
2020
Q2 		$2.69M Buy
23,951
+10,073
+73% +$1.07M 0.02% 532
2020
Q1 		$1.25M Sell
13,878
-50,001
-78% -$4.91M 0.01% 587
2019
Q4 		$6.91M Buy
63,879
+6,440
+11% +$689K 0.05% 400
2019
Q3 		$5.63M Buy
57,439
+45,653
+387% +$5.15M 0.04% 425
2019
Q2 		$1.54M Buy
11,786
+2,755
+31% +$355K 0.01% 605
2019
Q1 		$1.22M Sell
9,031
-352
-4% -$43.8K 0.01% 668
2018
Q4 		$912K Buy
9,383
+177
+2% +$20.9K 0.01% 717
2018
Q3 		$1.28M Hold
9,206
– – 0.01% 665
2018
Q2 		$1.14M Sell
9,206
-444
-5% -$51.9K 0.01% 716
2018
Q1 		$1.08M Buy
9,650
+561
+6% +$67.1K 0.01% 722
2017
Q4 		$1.09M Sell
9,089
-312
-3% -$38K 0.01% 719
2017
Q3 		$1.32M Sell
9,401
-776
-8% -$105K 0.01% 707
2017
Q2 		$1.24M Sell
10,177
-158,667
-94% -$18.5M 0.01% 719
2017
Q1 		$20.5M Buy
168,844
+63,695
+61% +$8.21M 0.19% 122
2016
Q4 		$12.9M Sell
105,149
-13,858
-12% -$1.7M 0.12% 223
2016
Q3 		$14.6M Buy
119,007
+24,466
+26% +$3.15M 0.12% 229
2016
Q2 		$11M Sell
94,541
-44,196
-32% -$6.27M 0.09% 297
2016
Q1 		$19.3M Sell
138,737
-46,536
-25% -$6.83M 0.16% 163
2015
Q4 		$35.3M Sell
185,273
-5,199
-3% -$908K 0.3% 83
2015
Q3 		$29.8M Sell
190,472
-21,342
-10% -$3.89M 0.26% 98
2015
Q2 		$38.3M Buy
211,814
+23,654
+13% +$4.08M 0.31% 81
2015
Q1 		$32.6M Sell
188,160
-54,447
-22% -$9.86M 0.25% 105
2014
Q4 		$44.9M Buy
242,607
+197,679
+440% +$36.6M 0.36% 70
2014
Q3 		$7.45M Buy
44,928
+4,237
+10% +$696K 0.06% 346
2014
Q2 		$6.36M Sell
40,691
-4,382
-10% -$692K 0.05% 402
2014
Q1 		$6.86M Sell
45,073
-8,618
-16% -$1.37M 0.05% 363
2013
Q4 		$7.14M Buy
53,691
+1,056
+2% +$127K 0.05% 331
2013
Q3 		$6.11M Buy
52,635
+27,328
+108% +$3M 0.05% 340
2013
Q2 		$2.33M Buy
+25,307
New +$2.44M 0.02% 575

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

BNP Paribas Asset Management's ALXN Position: Q3 2021 in Review

BNP Paribas Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 180,816 shares — an estimated $33.2M sold.

BNP Paribas Asset Management first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $44.9M in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • BNP Paribas Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BNP Paribas Asset Management sold 180,816 Alexion Pharmaceuticals shares in Q3 2021, an estimated $33.2M.
  • BNP Paribas Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • BNP Paribas Asset Management's Alexion Pharmaceuticals position peaked at $44.9M in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on BNP Paribas Asset Management's 13F filing for Q3 2021, filed 8 Nov 2021.